首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   707394篇
  免费   48986篇
  国内免费   1311篇
耳鼻咽喉   9172篇
儿科学   23299篇
妇产科学   17643篇
基础医学   110580篇
口腔科学   19970篇
临床医学   63870篇
内科学   134827篇
皮肤病学   16169篇
神经病学   49553篇
特种医学   25772篇
外国民族医学   76篇
外科学   104774篇
综合类   14825篇
现状与发展   2篇
一般理论   160篇
预防医学   51468篇
眼科学   16384篇
药学   54004篇
  3篇
中国医学   2361篇
肿瘤学   42779篇
  2019年   5472篇
  2018年   7898篇
  2017年   6151篇
  2016年   6876篇
  2015年   7595篇
  2014年   10319篇
  2013年   15455篇
  2012年   20581篇
  2011年   21579篇
  2010年   12766篇
  2009年   11976篇
  2008年   20068篇
  2007年   21585篇
  2006年   21969篇
  2005年   20504篇
  2004年   20070篇
  2003年   18993篇
  2002年   18510篇
  2001年   36384篇
  2000年   36935篇
  1999年   30410篇
  1998年   7890篇
  1997年   6676篇
  1996年   6980篇
  1995年   6637篇
  1994年   6104篇
  1993年   5604篇
  1992年   23004篇
  1991年   22968篇
  1990年   22336篇
  1989年   22095篇
  1988年   20056篇
  1987年   19428篇
  1986年   18478篇
  1985年   17321篇
  1984年   12706篇
  1983年   10753篇
  1982年   5921篇
  1979年   11525篇
  1978年   8134篇
  1977年   6841篇
  1976年   6603篇
  1975年   7272篇
  1974年   8503篇
  1973年   8148篇
  1972年   7662篇
  1971年   7130篇
  1970年   6879篇
  1969年   6308篇
  1968年   5781篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
82.
83.
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.  相似文献   
84.
Biliopancreatic diversion is a very effective method for weight reduction. In some instances it is too effective and needs to be revised.  相似文献   
85.
86.
In 1983, 1623 primary and secondary schoolchildren took part in a health survey which was organized by the Busselton Population Studies Group. Age, sex, weight, height and country of birth were recorded for each child. Where possible, the country of birth of parents and the occupation of the father were extracted from previous Busselton surveys of adults. Compared with Perth schoolchildren, the difference in the attained weight and height of Busselton children at any age was small. This was so even though the two communities differ in location (rural compared with metropolitan), in ethnic origin (mainly British compared with diverse origins) and, probably, in social-rank distribution. Data from the two communities showed that a similar small secular increase in height had occurred since 1970/1971. This increase averaged at 1.2 cm for children at each year of age in Busselton and 1.5 cm to 1.6 cm for children in Perth.  相似文献   
87.
88.
A novel approach for modelling the biological activity of organic molecules, which requires simultaneous consideration of the influence of all factors (topological, steric, hydrophobic, and electronic) that determine the bioactivity, is used to study the interaction of a series of benzoates with anti-p-(p'-azophenylazo)benzoate antibody. The results obtained suggest that this biological interaction proceeds by a two-step stereospecific mechanism. The first step requires a geometrical correspondence between the benzoates and the cavity in the biomacromolecule, which enables the pharmacophore to come into close contact with the receptor. The second step is the orbitally controlled electronic interaction between the active parts of the benzoates and the antibody. The electronic interaction results from pi-charge transfer from the pharmacophore to the biomacromolecule and from the formation of pi-complexes. A proposed mathematical model for this biological interaction exhibits some statistical advantages over existing models.  相似文献   
89.
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号